PL3334454T3 - Kompozycje mycoplasma bovis - Google Patents

Kompozycje mycoplasma bovis

Info

Publication number
PL3334454T3
PL3334454T3 PL16757118.1T PL16757118T PL3334454T3 PL 3334454 T3 PL3334454 T3 PL 3334454T3 PL 16757118 T PL16757118 T PL 16757118T PL 3334454 T3 PL3334454 T3 PL 3334454T3
Authority
PL
Poland
Prior art keywords
compositions
mycoplasma bovis
bovis
mycoplasma
bovis compositions
Prior art date
Application number
PL16757118.1T
Other languages
English (en)
Inventor
Glenn Francis Browning
Philip Francis Markham
Marc Serge Marenda
Fred H. Weber
Suman MAHAN
Original Assignee
Zoetis Services Llc
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc, The University Of Melbourne filed Critical Zoetis Services Llc
Publication of PL3334454T3 publication Critical patent/PL3334454T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL16757118.1T 2015-08-14 2016-08-11 Kompozycje mycoplasma bovis PL3334454T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205125P 2015-08-14 2015-08-14
PCT/US2016/046572 WO2017030901A1 (en) 2015-08-14 2016-08-11 Mycoplasma bovis compositions

Publications (1)

Publication Number Publication Date
PL3334454T3 true PL3334454T3 (pl) 2023-01-30

Family

ID=56800367

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16757118.1T PL3334454T3 (pl) 2015-08-14 2016-08-11 Kompozycje mycoplasma bovis

Country Status (23)

Country Link
US (2) US11389518B2 (pl)
EP (2) EP4137152A1 (pl)
JP (1) JP6675484B2 (pl)
CN (3) CN108135989B (pl)
AU (2) AU2016307935B2 (pl)
BR (1) BR112018002919B1 (pl)
CA (1) CA2995101A1 (pl)
CY (2) CY1125699T1 (pl)
DK (1) DK3334454T3 (pl)
ES (1) ES2933623T3 (pl)
FI (1) FI3334454T3 (pl)
FR (1) FR23C1037I2 (pl)
HR (1) HRP20221440T1 (pl)
HU (2) HUE060545T2 (pl)
LT (2) LT3334454T (pl)
LU (1) LUC00319I2 (pl)
MX (1) MX389685B (pl)
NL (1) NL301244I2 (pl)
PL (1) PL3334454T3 (pl)
PT (1) PT3334454T (pl)
SI (1) SI3334454T1 (pl)
WO (1) WO2017030901A1 (pl)
ZA (1) ZA201800956B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022314B (zh) * 2018-08-06 2021-08-13 北京华夏兴洋生物科技有限公司 一株牛支原体及其在疫苗研制中的应用
CN111471695A (zh) * 2020-05-11 2020-07-31 吉林农业大学 牛支原体免疫磁珠的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2000507092A (ja) 1996-02-28 2000-06-13 バイエル・アクチエンゲゼルシヤフト 外来dnaを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE512231T1 (de) 1998-02-27 2011-06-15 Univ Pennsylvania Impfstoffe, immuntherapeutika und verfahren zur anwendung derselben
PT1061955E (pt) 1998-03-13 2005-08-31 Wyeth Corp Composicao de polinucleotido, metodo de preparacao e sua utilizacao
PT1117435E (pt) 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
BR0015398A (pt) 1999-11-08 2002-06-25 Biomune Vacinas para mycoplasma bovis e processos de uso
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
GB0110851D0 (en) 2001-05-03 2001-06-27 Mini Agriculture & Fisheries Vaccine
AU2002346249B2 (en) 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
US7332174B2 (en) 2001-06-07 2008-02-19 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
EP2320943B1 (en) 2008-07-03 2016-02-17 Iowa State University Research Foundation, Inc. Cattle vaccines
MX2011004316A (es) * 2008-10-31 2011-06-16 Boehringer Ingelheim Vetmed Uso de antigenos diversos que incluyen antigenos de mycoplasma bovis en composicion de vacuna multivalente.
US20120045475A1 (en) * 2009-02-20 2012-02-23 Australian Poultry Crc Pty Limited Live attenuated vaccines
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
HUE060545T2 (hu) 2023-03-28
JP2018523708A (ja) 2018-08-23
US20220296694A1 (en) 2022-09-22
BR112018002919B1 (pt) 2024-02-27
WO2017030901A1 (en) 2017-02-23
SI3334454T1 (sl) 2023-02-28
EP3334454B1 (en) 2022-10-19
FI3334454T3 (fi) 2023-01-13
EP4137152A1 (en) 2023-02-22
CN115141772A (zh) 2022-10-04
CN108135989B (zh) 2022-08-09
AU2016307935A1 (en) 2018-02-22
PT3334454T (pt) 2022-12-20
HK1251478A1 (en) 2019-02-01
CY1125699T1 (el) 2024-02-16
NZ778923A (en) 2025-05-02
US20190255166A1 (en) 2019-08-22
HRP20221440T1 (hr) 2023-02-03
LT3334454T (lt) 2022-12-27
BR112018002919A2 (pt) 2018-09-18
EP3334454A1 (en) 2018-06-20
CY2023020I2 (el) 2024-02-16
HUS2300032I1 (hu) 2024-07-28
AU2022231761B2 (en) 2025-09-18
NL301244I2 (nl) 2023-11-01
NL301244I1 (nl) 2023-10-04
MX389685B (es) 2025-03-20
DK3334454T3 (da) 2022-11-14
CA2995101A1 (en) 2017-02-23
CN115141773A (zh) 2022-10-04
US11389518B2 (en) 2022-07-19
ZA201800956B (en) 2018-12-19
LUC00319I2 (pl) 2026-02-02
NZ739767A (en) 2025-05-02
LTPA2026509I1 (pl) 2026-03-25
CN108135989A (zh) 2018-06-08
AU2016307935B2 (en) 2022-08-18
JP6675484B2 (ja) 2020-04-01
FR23C1037I1 (fr) 2023-12-08
FR23C1037I2 (fr) 2025-12-19
CY2023020I1 (el) 2024-02-16
AU2022231761A1 (en) 2022-10-06
ES2933623T3 (es) 2023-02-10
MX2018001841A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
SG11201705415YA (en) Multi-supplement compositions
IL257131A (en) Preparations
GB201515387D0 (en) Compositions
GB201501598D0 (en) Compositions
IL256559B1 (en) Flinbolin preparations
GB201506827D0 (en) Composition
GB201505527D0 (en) Composition
GB201515391D0 (en) Compositions
GB201508510D0 (en) Curling compositions
GB201506829D0 (en) Composition
GB201506830D0 (en) Composition
GB201506825D0 (en) Composition
GB201504665D0 (en) Composition
SI3349766T1 (sl) Antihemoragični sestavki
HUS2300032I1 (hu) Mycoplasma bovis-készítmények
GB201504307D0 (en) Composition
GB201506828D0 (en) Composition
GB201505520D0 (en) Composition
GB2538335B (en) Compositions
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition
HUE050837T2 (hu) Készítmények
GB201522892D0 (en) Compositions
GB201511469D0 (en) Compositions
GB201507673D0 (en) Compositions